Reaktionsgleichung
[CH:1]1([NH:7][C:8]2[N:13]3[N:14]=[C:15]([NH2:17])[N:16]=[C:12]3[CH:11]=[CH:10][CH:9]=2)[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1.[O:18]1[CH2:23][CH2:22][N:21]([C:24]2[CH:32]=[CH:31][C:27]([C:28](Cl)=[O:29])=[CH:26][N:25]=2)[CH2:20][CH2:19]1>>[CH:1]1([NH:7][C:8]2[N:13]3[N:14]=[C:15]([NH:17][C:28](=[O:29])[C:27]4[CH:31]=[CH:32][C:24]([N:21]5[CH2:20][CH2:19][O:18][CH2:23][CH2:22]5)=[N:25][CH:26]=4)[N:16]=[C:12]3[CH:11]=[CH:10][CH:9]=2)[CH2:2][CH2:3][CH2:4][CH2:5][CH2:6]1Komponenten
3
Versuchsvorschrift
The title compound was prepared following procedure described for intermediate B1, but starting from N5-cyclohexyl[1,2,4]triazolo[1,5-a]pyridine-2,5-diamine ((A9), 174 mg; 0.75 mmol; 1.0 eq.) and 6-morpholinonicotinoyl chloride (255 mg; 1.12 mmol; 1.5 eq.) as a white solid (15 mg, 5%). HPLC, Rt: 2.83 min. (purity 99.0%). LC/MS, M+(ESI): 422.2, M−(ESI): 420.1.
Quellen und Nachweise
- ORD-Eintrag
- ord-0c6dbc99625f4589afc87b0796503f30
- Quelldatensatz
- uspto-grants-2012_09
- Patentnummer
- US08263595B2
Verknüpfte Notizen
Wird geladen…